» Articles » PMID: 30138393

Distinct Substrate Specificity and Physicochemical Characterization of Native Human Hepatic Thymidine Phosphorylase

Overview
Journal PLoS One
Date 2018 Aug 24
PMID 30138393
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Thymidine phosphorylase (TP; EC 2.4.2.4) is involved regulation of intra- or extracellular thymidine concentration, angiogenesis, cancer chemotherapy, radiotherapy, as well as tumor imaging. Although the liver is main site of pyrimidine metabolism and contains high levels of TP, nonetheless, purification and characterization of human hepatic TP has not been accomplished. We here report the purification and characterization of native human hepatic TP. The enzyme was purified to apparent homogeneity by a procedure shorter and more efficient than previously reported methods. Human hepatic TP has an apparent Kthymidine of 285 ± 55 μM. Like the enzyme from other tissues, it is highly specific to 2'-deoxyribosides. However, in contrast to TP from other normal tissues, the hepatic enzyme is active in the phosphorolysis of 5'-deoxy-5-fluorouridine, and the riboside 5-fluorouridine. Furthermore, native hepatic TP exists in different aggregates of 50 kDa subunits, with unknown aggregation factor(s) while TP from extra tissues exists as a homodimer. Isoelectric point was determined as 4.3. A total of 65 residues in the N-terminal were sequenced. The sequence of these 65 amino acids in hepatic TP has 100% sequence and location homology to the deduced amino acid sequence of the platelet derived-endothelial cell growth factor (PD-ECGF) cDNA. However, and contrary to PD-ECGF, the N-terminal of hepatic TP is blocked. The block was neither N-formyl nor pyrrolidone carboxylic acid moieties. The differences in substrate specificities, existence in multimers, and weak interaction with hydroxyapatite resin strongly suggest that hepatic TP is distinct from the enzyme in normal extrahepatic tissues. These results may have important clinical implications when TP is involved in activation or deactivation of chemotherapeutic agents in different tissues.

Citing Articles

A novel thymidine phosphorylase to synthesize (halogenated) anticancer and antiviral nucleoside drugs in continuous flow.

Benitez-Mateos A, Klein C, Roura Padrosa D, Paradisi F Catal Sci Technol. 2022; 12(20):6231-6238.

PMID: 36325519 PMC: 9575728. DOI: 10.1039/d2cy00751g.


Engineering of the Recombinant Expression and PEGylation Efficiency of the Therapeutic Enzyme Human Thymidine Phosphorylase.

Karamitros C, Somody C, Agnello G, Rowlinson S Front Bioeng Biotechnol. 2022; 9:793985.

PMID: 34976980 PMC: 8718881. DOI: 10.3389/fbioe.2021.793985.

References
1.
Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y . Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. 1995; 55(8):1687-90. View

2.
Johnson M, Correia J, YPHANTIS D, Halvorson H . Analysis of data from the analytical ultracentrifuge by nonlinear least-squares techniques. Biophys J. 1981; 36(3):575-88. PMC: 1327647. DOI: 10.1016/S0006-3495(81)84753-4. View

3.
Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L . Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2001; 45(4):291-7. DOI: 10.1007/s002800050043. View

4.
Janion C, SHUGAR D . Thymidine phosphorylase and other enzymes in regenerating rat liver. Acta Biochim Pol. 1961; 8:337-44. View

5.
Patterson A, Zhang H, Moghaddam A, Bicknell R, Talbot D, Stratford I . Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer. 1995; 72(3):669-75. PMC: 2033908. DOI: 10.1038/bjc.1995.392. View